MapLight Therapeutics, Inc. (MPLT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MapLight Therapeutics, Inc. (MPLT) Healthcare & Pipeline Overview

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for central nervous system disorders, including treatments for schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, Parkinson's disease, and agitation-related disorders. The company targets neural circuits causally linked to disease for therapeutic modulation.

What Is the Investment Thesis for MPLT?

MapLight Therapeutics presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The company's focus on CNS disorders, an area with significant unmet medical need, offers substantial potential upside if its drug candidates prove effective. Key value drivers include the successful completion of clinical trials for its lead compounds, particularly ML-007C-MA for schizophrenia and Alzheimer's disease psychosis, and ML-004 for autism spectrum disorder. Positive clinical data could lead to significant increases in valuation. However, the company's success is highly dependent on the outcomes of its clinical trials, regulatory approvals, and its ability to secure funding to support its research and development activities. The negative beta of -2.79 suggests the stock price moves inversely to the market, but this may be due to its early stage and speculative nature.

Based on FMP financials and quantitative analysis

MPLT Key Highlights

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on central nervous system disorders.

• The company's lead product, ML-007C-MA, targets schizophrenia and Alzheimer's disease psychosis.
• ML-004 is being developed for social communication deficit and irritability in autism spectrum disorder.
• ML-021 aims to treat motor deficits in Parkinson's disease.
• ML-009 is a G-protein-coupled receptor 52 positive allosteric modulator for hyperactivity, impulsivity and agitation-related disorders.

Who Are MPLT's Competitors?

MPLT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MPLT's Key Strengths?

Novel neural circuit targeting platform.

• Diverse pipeline of CNS drug candidates.
• Experienced management team.
• Focus on areas with high unmet medical need.

What Are MPLT's Weaknesses?

Clinical-stage company with no approved products.

• High dependence on clinical trial outcomes.
• Limited financial resources.
• Competition from larger pharmaceutical companies.

What Could Drive MPLT Stock Higher?

MPLT catalyst: Phase 1 clinical trial results for ML-007C-MA in Schizophrenia and Alzheimer's Disease Psychosis expected in Q4 2026.

• Initiation of Phase 2 clinical trial for ML-004 in Autism Spectrum Disorder anticipated in Q1 2027.
• Continued development and expansion of the neural circuit targeting platform.
• Potential partnerships and collaborations with larger pharmaceutical companies.

What Are the Key Risks for MPLT?

Negative return on equity (-69.1%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Delays or rejection of regulatory approvals.
• Competition from established pharmaceutical companies with existing CNS therapies.
• Challenges in securing sufficient funding to support research and development activities.
• Intellectual property disputes or challenges to patent protection.

What Are the Growth Opportunities for MPLT?

• Successful clinical trials and regulatory approval for ML-007C-MA could provide MapLight with a significant revenue stream. The timeline for this growth opportunity depends on the progression of clinical trials, with potential for market entry within the next 3-5 years.
• Development of ML-004 for Autism Spectrum Disorder: The prevalence of autism spectrum disorder (ASD) is increasing, driving demand for effective treatments. ML-004 targets social communication deficits and irritability associated with ASD, representing a significant market opportunity. Positive clinical trial results could position MapLight as a key player in the ASD therapeutics market, with potential for commercialization within 4-6 years.
• Progress of ML-021 for Parkinson's Disease: Parkinson's disease affects millions worldwide, creating a substantial market for therapies addressing motor deficits. ML-021 aims to improve motor function in Parkinson's patients, offering a potential improvement in quality of life. Successful development and commercialization of ML-021 could contribute significantly to MapLight's revenue, with a potential timeline of 5-7 years.
• Expansion of Pipeline through Neural Circuit Targeting Platform: MapLight's platform for identifying and targeting neural circuits linked to disease offers a pathway for expanding its pipeline beyond its current candidates. This platform could lead to the discovery and development of new therapies for a range of CNS disorders, creating long-term growth opportunities. The timeline for this growth opportunity is dependent on the success of ongoing research and development efforts, with potential for new drug candidates to emerge within the next 2-4 years.
• Partnerships and Collaborations with Larger Pharmaceutical Companies: MapLight could pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to funding, expertise, and distribution networks, enhancing MapLight's growth prospects. The timing and success of these partnerships are uncertain, but they represent a potential catalyst for growth in the near to medium term.

What Are MPLT's Competitive Advantages?

• Proprietary neural circuit targeting platform.
• Pipeline of novel drug candidates targeting specific CNS disorders.
• Intellectual property protection for its drug candidates and platform technology.
• Expertise in CNS drug development.

What Does MPLT Do?

MapLight Therapeutics, Inc., founded in 2018 and based in Redwood City, California, is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for patients suffering from debilitating central nervous system (CNS) disorders. Originally incorporated as Alvarado Therapeutics, Inc., the company rebranded as MapLight Therapeutics in August 2019, reflecting its focus on mapping and modulating neural circuits. MapLight operates as a subsidiary of Catalyst4, Inc. The company's pipeline includes several drug candidates targeting a range of CNS conditions. ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being developed for the treatment of schizophrenia and Alzheimer's disease psychosis. ML-004 is designed to address social communication deficits and irritability in autism spectrum disorder. ML-021 targets motor deficits in Parkinson's disease. ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is being developed for the treatment of hyperactivity, impulsivity, and agitation-related disorders. MapLight's approach involves identifying neural circuits causally linked to disease and then developing therapies to modulate those circuits, offering a targeted approach to CNS drug development.

What Products and Services Does MPLT Offer?

• Develop novel therapies for central nervous system disorders.
• Focus on treatments for schizophrenia and Alzheimer's disease psychosis.
• Develop therapies for social communication deficit and irritability in autism spectrum disorder.
• Create treatments for motor deficits in Parkinson's disease.
• Develop treatments for hyperactivity, impulsivity, and agitation-related disorders.
• Identify neural circuits causally linked to disease.
• Target those circuits for therapeutic modulation.

How Does MPLT Make Money?

• Develops pharmaceutical products through research and clinical trials.
• Seeks regulatory approval for its drug candidates.
• Potentially commercializes approved drugs directly or through partnerships.
• Generates revenue through sales of approved pharmaceutical products.

What Industry Does MPLT Operate In?

The biotechnology industry is characterized by high levels of innovation, intense competition, and significant regulatory hurdles. Companies like MapLight Therapeutics operate in a landscape dominated by larger pharmaceutical firms and specialized biotech companies. The CNS therapeutics market is substantial, driven by the increasing prevalence of neurological and psychiatric disorders. Success in this market requires not only scientific innovation but also the ability to navigate complex clinical trials and regulatory pathways. MapLight's focus on specific neural circuits offers a potentially differentiated approach within this competitive environment.

Who Are MPLT's Key Customers?

• Patients suffering from schizophrenia and Alzheimer's disease psychosis.
• Individuals with autism spectrum disorder.
• Patients with Parkinson's disease.
• Individuals with hyperactivity, impulsivity, and agitation-related disorders.

Wall Street analysts project MapLight Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-5.15.

MPLT Valuation & Market Position

With a $477M market cap, MapLight Therapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, MPLT's quantitative score of 41/100 is below the peer average of 86/100.

Return on equity for MapLight Therapeutics, Inc. stands at -69.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -47.6%, showing how much profit it generates from its asset base. A current ratio of 22.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.4%, the inverse of the P/E and a quick read on earnings relative to price.

MapLight Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 12.07 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

MapLight Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Christopher A. Kroeger. MPLT has traded publicly since 2025.

MPLT Financials

MPLT Latest News

MPLT Analyst Consensus

MPLT MoonshotScore

MapLight Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources